financetom
Business
financetom
/
Business
/
DelphX Capital Edging Up As Says Poised for First Commercial Transactions In Its CRS Program
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DelphX Capital Edging Up As Says Poised for First Commercial Transactions In Its CRS Program
Dec 30, 2024 7:59 AM

10:37 AM EST, 12/30/2024 (MT Newswires) -- DelphX Capital Markets ( DPXCF ) , involved with innovative structured products for the fixed income market, was edging up Monday after saying it was set to deliver first commercial transactions in its proprietary Credit Rating Securities (CRS) program, "paving the way for significant market adoption and sustained positive cash flows".

The company said it looks forward to increased CRS adoption following its initial transactions, supported by continuous engagement with new market participants. DelphX added that the platform's innovative design allows insurance companies, hedge funds, and institutional investors to mitigate downgrade risks while unlocking new returns.

"The last two years have been a test of resilience and innovation as we reimagined fixed income risk management. Today, as we stand on the cusp of executing our first CRS transactions, the excitement across our team is palpable. DelphX is delivering the most significant innovation in fixed income markets in over a decade, and we believe the market's response will reflect the innovative nature of CRS," said DelphX Chief Executive Patrick Wood.

Shares of the company were last seen up $0.005 at $0.135 in early morning trade on the TSX Venture Exchange.

Price: 0.14, Change: +0.01, Percent Change: +3.85

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mirum Pharmaceuticals Insider Sold Shares Worth $320,644, According to a Recent SEC Filing
Mirum Pharmaceuticals Insider Sold Shares Worth $320,644, According to a Recent SEC Filing
Jan 8, 2025
04:48 PM EST, 01/08/2025 (MT Newswires) -- Christopher Peetz, Director, CEO, on January 07, 2025, sold 7,489 shares in Mirum Pharmaceuticals ( MIRM ) for $320,644. Following the Form 4 filing with the SEC, Peetz has control over a total of 327,929 shares of the company, with 119,359 shares held directly and 208,570 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1759425/000141588925001143/xslF345X05/form4-01082025_090146.xml ...
Weatherford International Insider Sold Shares Worth $346,007, According to a Recent SEC Filing
Weatherford International Insider Sold Shares Worth $346,007, According to a Recent SEC Filing
Jan 8, 2025
04:40 PM EST, 01/08/2025 (MT Newswires) -- David John Reed, Executive Vice President, Chief Commercial Officer, on January 06, 2025, sold 4,762 shares in Weatherford International ( WFRD ) for $346,007. Following the Form 4 filing with the SEC, Reed has control over a total of 11,109 shares of the company, with 11,109 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1603923/000160392325000014/xslF345X05/wk-form4_1736371916.xml ...
Blade Air Mobility Insider Sold Shares Worth $525,020, According to a Recent SEC Filing
Blade Air Mobility Insider Sold Shares Worth $525,020, According to a Recent SEC Filing
Jan 8, 2025
04:43 PM EST, 01/08/2025 (MT Newswires) -- William A. Heyburn, Chief Financial Officer, on January 06, 2025, sold 104,570 shares in Blade Air Mobility ( BLDE ) for $525,020. Following the Form 4 filing with the SEC, Heyburn has control over a total of 1,222,220 shares of the company, with 1,222,220 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1779128/000177912825000002/xslF345X05/wk-form4_1736372305.xml ...
Avadel Pharmaceuticals Preliminary Q4 Net Product Revenue Rises; 2025 Outlook Set; Shares Fall After Hours
Avadel Pharmaceuticals Preliminary Q4 Net Product Revenue Rises; 2025 Outlook Set; Shares Fall After Hours
Jan 8, 2025
04:41 PM EST, 01/08/2025 (MT Newswires) -- Avadel Pharmaceuticals ( AVDL ) reported preliminary Q4 net product revenue Wednesday of $50 million, up from $19.5 million a year earlier. Analysts polled by FactSet expect $52 million. The company expects 2025 net product revenue of $240 million to $260 million. Analysts surveyed by FactSet expect $288.9 million. Shares of the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved